Drug Trial Radar · NCT06077331
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 28, 2023
Primary completion
Jul 31, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
Conditions
- Psoriasis
Interventions
HS-10374 tablets 1mgDrug
Administered orally QD for 12 weeks
HS-10374 tablets 5mgDrug
Administered orally QD for 12 weeks
HS-10374-matched placebo tabletsDrug
Administered orally QD for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with moderate to severe plaque psoriasis achieving PASI 75 response at Week 12Time frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.